PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
45.87%
Revenue growth of 45.87% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
67.35%
Gross profit growth of 67.35% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
1734.07%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.89%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
1734.07%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.02%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-29.67%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-43.13%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-35.00%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
412.48%
OCF growth of 412.48% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
-1793.46%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1010.27%
OCF/share CAGR of 1010.27% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
1010.27%
OCF/share CAGR of 1010.27% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
34659.91%
3Y OCF/share growth of 34659.91% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
390.48%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 23.11% over a decade. Joel Greenblatt might see a standout compounder of earnings.
390.48%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 3.02%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
631.14%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 9.17%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
795.87%
Equity/share CAGR of 795.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
795.87%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 10.76%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
993.82%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 20.69%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.78%
AR growth of 17.78% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
30.20%
Inventory growth of 30.20% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
126.50%
Asset growth of 126.50% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
105.08%
BV/share growth of 105.08% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
No Data
No Data available this quarter, please select a different quarter.
2902.62%
We slightly increase R&D while Drug Manufacturers - Specialty & Generic is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
19.50%
SG&A growth of 19.50% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.